AHCL

Anlon Healthcare Share Price

 

 

Start SIP in AHCL

Start SIP

Performance

  • Low
  • ₹120
  • High
  • ₹124
  • 52 Week Low
  • ₹91
  • 52 Week High
  • ₹173
  • Open Price₹122
  • Previous Close₹122
  • Volume32,896
  • 50 DMA₹137.20
  • 100 DMA₹134.76
  • 200 DMA-

Investment Returns

  • Over 1 Month -18.91%
  • Over 3 Month -4.83%
  • Over 6 Month + 34.51%
  • Over 1 Year + 34.51%

Smart Investing Starts Here Start SIP with Anlon Healthcare for Steady Growth!

Invest Now

Anlon Healthcare Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 651
  • P/B Ratio
  • 3
  • Average True Range
  • 6.72
  • EPS
  • 3.86
  • Dividend Yield
  • 0
  • MACD Signal
  • -4.02
  • RSI
  • 30.73
  • MFI
  • 21.26

Anlon Healthcare Financials

Anlon Healthcare Technicals

EMA & SMA

Current Price
₹122.40
0 (0%)
pointer
  • Bearish Moving Average 13
  • Bullish Moving Average 0
  • 20 Day
  • ₹133.22
  • 50 Day
  • ₹137.20
  • 100 Day
  • ₹134.76
  • 200 Day
  • -

Resistance and Support

123.1 Pivot Speed
  • R3 127.39
  • R2 126.19
  • R1 124.30
  • S1 121.21
  • S2 120.01
  • S3 118.12

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Anlon Healthcare, manufactures pharmaceutical bulk drugs and intermediates with advanced API facilities and strong R&D. Its products meet FDA, PMDA, KFDA, cGMP, and WHO-GMP standards, serving global healthcare needs with quality, compliance, and speed-to-market focus.

Anlon Healthcare Ltd has an operating revenue of Rs. 229.95 Cr. on a trailing 12-month basis. An annual revenue growth of 81% is outstanding, Pre-tax margin of 22% is great, ROE of 25% is exceptional. The company has a reasonable debt to equity of 48%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 94 which is a GREAT score indicating consistency in earnings, a RS Rating of 87 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 67 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Anlon Healthcare Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-11 Quarterly Results
2025-10-16 Others Inter-alia, to consider 1. The Expansion plan of the Companys business operation through existing facility expansion and/or acquisition strategy. 2. Other business matters.
2025-09-27 Others Inter-alia, to consider 1. Proposal for purchase of immovable property (Commercial Office) situated at Golden Crown, New 150 Feet Ring Road, Rajkot - 360005, Gujarat. 2. Other business matters.

Anlon Healthcare F&O

Anlon Healthcare Shareholding Pattern

52.68%
0.09%
0.23%
23.58%
23.42%

About Anlon Healthcare

  • NSE Symbol
  • AHCL
  • BSE Symbol
  • 544497
  • Chairman & Managing Director
  • Mr. Punitkumar R Rasadia
  • ISIN
  • INE0Y8W01017

Similar Stocks to Anlon Healthcare

Anlon Healthcare FAQs

Anlon Healthcare share price is ₹122 As on 01 February, 2026 | 13:31

The Market Cap of Anlon Healthcare is ₹650.6 Cr As on 01 February, 2026 | 13:31

The P/E ratio of Anlon Healthcare is As on 01 February, 2026 | 13:31

The PB ratio of Anlon Healthcare is 3 As on 01 February, 2026 | 13:31

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23